Drugs / ALN-5288
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07214727 | Oct 2025 → Mar 2030 expected | Alzheimer disease | Alnylam Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALN-5288 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07214727 ↗ |
| Route | Intrathecal | “administered IT.” NCT07214727 ↗ |